Form 4: PDS Biotechnology Director Ilian Iliev Granted 22,700 Stock Options

PDS Biotechnology Corp (PDSB) announced that Director Ilian Iliev was granted 22,700 employee stock options with an exercise price of $1.75, vesting on the first anniversary of the grant date.

Summary

• Ilian Iliev, a Director of PDS Biotechnology Corp (PDSB), was granted 22,700 employee stock options.
• The options have an exercise price of $1.75 per share.
• The options were granted on June 11, 2025, and will expire on June 11, 2035.
• The stock options will vest in full and become fully exercisable on the first anniversary of the grant date, subject to Mr. Iliev's continued service as a director.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's financial interests with the long-term performance of the company and its shareholders, incentivizing growth and value creation.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• This is a standard form of compensation that helps retain key personnel and incentivize performance.

Future Outlook

The vesting schedule of the stock options implies an expectation of continued service from Director Ilian Iliev for at least one year from the grant date.

Management Comments

• Director Ilian Iliev was granted 22,700 employee stock options as part of his compensation.

Industry Context

The granting of stock options is a common practice in the biotechnology industry, particularly for companies focused on research and development, as it provides a long-term incentive for directors and executives whose contributions are critical to the company's future success and valuation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across the biotechnology sector and broader public companies, aiming to align leadership incentives with shareholder value creation.
• The vesting schedule (one-year cliff) is a common structure for director equity grants, similar to practices observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, though specific grant sizes and exercise prices vary based on company stage and market capitalization.

Related Party Transactions

• The grant of employee stock options to Director Ilian Iliev constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: While this specific grant is to a director, it reflects a broader compensation strategy that may include equity incentives for other employees.

Next Steps

• The stock options are expected to vest on the first anniversary of the grant date, subject to the director's continued service.

Key Dates

Keywords

PDS Biotechnology Corp, PDSB, Ilian Iliev, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Compensation, Biotechnology